CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia

SEATTLE, Feb. 3, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that following a meeting with the U.S. Food and Drug Administration ( " FDA " or " the Agency " ), CTI has reached agreement on an...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials